Machine learning approaches to predict gestational age in normal and complicated pregnancies via urinary metabolomics analysis.

Journal: Scientific reports
PMID:

Abstract

The elucidation of dynamic metabolomic changes during gestation is particularly important for the development of methods to evaluate pregnancy status or achieve earlier detection of pregnancy-related complications. Some studies have constructed models to evaluate pregnancy status and predict gestational age using omics data from blood biospecimens; however, less invasive methods are desired. Here we propose a model to predict gestational age, using urinary metabolite information. In our prospective cohort study, we collected 2741 urine samples from 187 healthy pregnant women, 23 patients with hypertensive disorders of pregnancy, and 14 patients with spontaneous preterm birth. Using gas chromatography-tandem mass spectrometry, we identified 184 urinary metabolites that showed dynamic systematic changes in healthy pregnant women according to gestational age. A model to predict gestational age during normal pregnancy progression was constructed; the correlation coefficient between actual and predicted weeks of gestation was 0.86. The predicted gestational ages of cases with hypertensive disorders of pregnancy exhibited significant progression, compared with actual gestational ages. This is the first study to predict gestational age in normal and complicated pregnancies by using urinary metabolite information. Minimally invasive urinary metabolomics might facilitate changes in the prediction of gestational age in various clinical settings.

Authors

  • Takafumi Yamauchi
    X-Tech Development Department, NTT DOCOMO, INC, 3-6 Hikarino-oka, Yokosuka, Kanagawa, 239-8536, Japan.
  • Daisuke Ochi
    X-Tech Development Department, NTT DOCOMO, INC, 3-6 Hikarino-oka, Yokosuka, Kanagawa, 239-8536, Japan.
  • Naomi Matsukawa
    Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan.
  • Daisuke Saigusa
    Department of Integrative Genomics, Tohoku University Tohoku Medical Megabank Organization, Sendai, Japan.
  • Mami Ishikuro
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan.
  • Taku Obara
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan.
  • Yoshiki Tsunemoto
    X-Tech Development Department, NTT DOCOMO, INC, 3-6 Hikarino-oka, Yokosuka, Kanagawa, 239-8536, Japan.
  • Satsuki Kumatani
    X-Tech Development Department, NTT DOCOMO, INC, 3-6 Hikarino-oka, Yokosuka, Kanagawa, 239-8536, Japan.
  • Riu Yamashita
    Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan.
  • Osamu Tanabe
    Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan.
  • Naoko Minegishi
    Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan.
  • Seizo Koshiba
    Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Hirohito Metoki
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan.
  • Shinichi Kuriyama
    Tohoku Medical Megabank Organization (ToMMo), Tohoku University, Sendai, Miyagi, Japan. kuriyama@med.tohoku.ac.jp.
  • Nobuo Yaegashi
    Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
  • Masayuki Yamamoto
  • Masao Nagasaki
    Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan.
  • Satoshi Hiyama
    X-Tech Development Department, NTT DOCOMO, INC, 3-6 Hikarino-oka, Yokosuka, Kanagawa, 239-8536, Japan.
  • Junichi Sugawara
    Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan. jsugawara@med.tohoku.ac.jp.